	Case 5:15-cv-05598 Document 1 Fil	led 12/08/15 Page 1 of 32				
1 2	MARTIN SCHMIDT, ESQ. (SBN 171673) mschmidt@nationalinjuryhelp.com SCHMIDT NATIONAL LAW GROUP 4241 Jutland Dr. Suite 200					
3	San Diego, CA 92117 Telephone: 800.214.1010					
4	Facsimile: 619.393.1777					
5	Attorney for Plaintiff CHRISTINE BARREIROS					
6						
7	IN THE UNITED STAT	TES DISTRICT COURT				
8	NORTHERN DISTRI	CT OF CALIFORNIA				
9	SAN FRANCIS	SCO DIVISION				
10						
11	CHRISTINE BARREIROS, an individual,	Case No.:				
12	Plaintiff,	COMPLAINT FOR DAMAGES AND				
13	V.	DEMAND FOR JURY TRIAL				
14	BAYER HEALTHCARE LLC, a Delaware	<ul><li>(1) Manufacturing</li><li>(2) Design Defect</li></ul>				
15	corporation; BAYER HEALTHCARE PHARMACEUTICALS, INC., a Deleware	(3) Negligence				
16	corporation; BAYER ESSURE, INC., a Delaware corporation; and DOES 1-10, inclusive	<ul><li>(4) Failure to warn</li><li>(5) Strict Liability</li></ul>				
17	Defendants	<ul><li>(6) Breach of Implied Warranty</li><li>(7) Breach of Express Warranty</li></ul>				
18	Derendants	(8) Negligent Misrepresentation				
19		<ul><li>(9) Fraudulent Misrepresentation</li><li>(10) Fraud by Concealment</li></ul>				
20						
20 21						
21	COMES NOW Plaintiff CHRISTINE F	BARREIROS, and files this Complaint seeking				
22	judgment against Defendants BAYER HEALTHCARE LLC; BAYER HEALTHCARE					
24	PHARMACEUTICALS, INC.; BAYER ESSURE, INC.; and DOES 1 through 10 inclusive,					
25	(hereinafter collectively referred to as "Defendants" or "Bayer") for personal injuries suffered as a					
26	result of Plaintiff CHRISTINE BARREIROS (her	reinafter "Plaintiff") being prescribed and using the				
27	defective and unreasonably dangerous product Es	ssure®. At all times relevant hereto, Essure® was				
28	manufactured, designed, formulated tested, packag	ged, labeled, produced, created, made, constructed,				
	COMPLAINT FOR DAMAGES A	1 ND DEMAND FOR JURY TRIAL				

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 2 of 32

assembled, marketed, advertised, distributed and sold by Defendants or by Conceptus, Inc. which
 merged with Bayer on or about April 28, 2013.

3

I.

### PARTIES, JURISDICTION AND VENUE

1. This Court has diversity subject matter jurisdiction over this action pursuant to 28 4 U.S.C. §1332(a): The district courts shall have original jurisdiction of all civil actions where the 5 matter in controversy exceeds the sum or value of \$75,000.00, exclusive of interest and costs, and is 6 between (1) citizens of different states. Damages to Plaintiff are estimated in good faith to exceed 7 the sum or value of \$75,000.00, exclusive of interest and costs. The Court also has personal 8 jurisdiction over the parties because Plaintiff submits to the jurisdiction of the Court and Defendants 9 systematically and continually conducts business here and Conceptus, Inc. ("Conceptus"), a wholly 10 owned subsidiary of Bayer A.G. and/or Bayer Healthcare LLC, is headquartered in Mountain View, 11 California. Conceptus, which is now part of Bayer, designed, developed, conducted clinical trials 12 and manufactured Essure® at its Mountain View, California facilities.

13

14

2. This Court has supplemental jurisdiction over the remaining common law and state claims pursuant to 28 U.S.C. §1367.

3. Venue is proper in this Court pursuant to 28 U.S.C. §1391 because a substantial part
of the events giving rise to Plaintiff's claims occurred, in part, in the Northern District of California,
including the design, clinical testing, marketing and manufacturing of the Essure® system.

18

4.

II.

At all times relevant hereto, Plaintiff is and was a resident of Mesa, Arizona.

19 5. Defendant BAYER HEALTHCARE LLC is a for-profit corporation incorporated in
20 the state of Delaware. Defendant is authorized to and does business throughout the states of
21 California and Arizona.

22 6. Defendant BAYER ESSURE INC. is a for-profit corporation incorporated in the state
 23 of Delaware. Defendant is authorized to and does business throughout the states of California and
 24 Arizona.

7. Defendant BAYER PHARMEUCITALS, INC., is a for-profit corporation
 incorporated in the state of Delaware. Defendant is authorized to and does business throughout the
 states of California and Arizona.

28

### FACTS AND ALLEGATIONS COMMON TO ALL CLAIMS

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 3 of 32

8. This Complaint is brought by Plaintiff who relied on express warranties of Defendants
 before being implanted with a female birth control device, known as "Essure." As a result of (1)
 Defendants negligence described *infra* and (2) her reliance on Defendants' warranties, Defendants'
 Essure® device was placed in both of her fallopian tubes. After the device was implanted, Plaintiff
 has suffered from migraines, severe abdominal, ovarian and pelvic pain, sharp, stabbing pain, pain
 during intercourse, heavy bleeding, emotional pain and mental anguish.

7

8

9

9. Essure® had Conditional Premarket Approval ("CPMA") by the Food and Drug Administration ("FDA"). As discussed herein, this CPMA became "invalid" and the product "adulterated" pursuant to the FDA due to Defendants' failure to comply with the CPMA order. As a result, Defendants' CPMA is "invalid" and its "adulterated" product, Essure®, should never have been marketed or sold to Plaintiff.

11

10

10. Plaintiff's first cause of action is based in Defendants' negligence in (1) failing to adequately train Plaintiff's implanting physician ("the implanting physician"); and (2) entrusting the implanting physician with specialized hysteroscopic equipment he was not qualified to use, and (3) distributing the product in an unreasonably dangerous manner, as fully discussed below.

15 11. The training, entrustment, of specialized hysteroscopic equipment to the implanting
16 physician and method of distribution did not have CPMA by the FDA.

17 12. Plaintiff's second cause of action is based entirely on the express warranties made by
18 Defendants to Plaintiff, which were relied upon by Plaintiff prior to having the device implanted.

19 13. Notwithstanding the fact that Plaintiff's two causes of action fall outside the purview
20 of the MDA, Defendants' CPMA is "invalid" and Essure® is an "adulterated" product per the FDA.

21

22

14. In short, according to the FDA, the CPMA order became invalid because Defendants failed to comply with any of the following express conditions:

(a) "Within 10 days after Defendant receives knowledge of any adverse reaction to
 report the matter to the FDA."

(b) "Report to the FDA whenever it receives information from any sources that
 reasonably suggests that the device may have caused or contributed to a serious injury."

The fact that Defendants failed to comply with these conditions is not a mere
 allegation made by Plaintiff. It is an FDA finding.

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 4 of 32

1 16. As discussed in detail *infra*, Defendants were cited by the FDA and the Department
 of Health for (1) failing to report and actively concealing 8 perforations which occurred as a
 result of Essure®; (2) erroneously using non-conforming material in the manufacturing of Essure®;
 (3) failing to use pre-sterile and post-sterile cages; (4) manufacturing Essure® at an unlicensed
 facility and (5) manufacturing Essure® for three years without a license to do so.

6

17. These violations invalidated the CPMA, rendering the product "adulterated"precluding Defendants from marketing or selling Essure® per the FDA, and, more importantly, endangered the life of Plaintiff and the safety of the public.

8

7

18. Defendants actively concealed these violations and never advised Plaintiff of the
 same. Had Plaintiff known that <u>Defendants were concealing adverse reactions, not using</u>
 conforming material approved by the FDA, not using sterile cages, operating out of an
 unlicensed facility, and manufacturing medical devices without a license to do the same, she
 never would have had Essure® implanted.

13

#### A. <u>Description Of Essure® And How It Works</u>

14 19. Essure® is a permanent form of female birth control (female sterilization). In short,
15 the device is intended to cause bilateral occlusions (blockage) of the fallopian tubes by the insertion
16 of micro-inserts into the fallopian tubes which then anchor and elicit tissue growth, theoretically
17 causing the blockage.

18 20. Essure® consists of (1) micro-inserts; (2) a disposable delivery system; and (3) a
19 disposable split introducer. All components are intended for a single use.

20 21. The micro-inserts are comprised of two metal coils which are placed in a woman's
21 fallopian tubes via Defendants' disposable delivery system and under hysteroscopic guidance
22 (camera).

22. The hysteroscopic equipment needed to place Essure® was manufactured by a third
 party, is not part of Defendants' CPMA, and is not a part of Essure®. However, because Plaintiff's
 implanting physician did not have such equipment, Defendants provided it to that they could sell
 Essure®.

27

23. The coils are comprised on nickel, steel, nitinol, and PET fibers.

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 5 of 32

- Defendants' disposable delivery system consists of a single handle which contains a
   delivery wire, release catheter, and delivery catheter. The micro-inserts are attached to the delivery
   wire. The delivery handle controls the device, delivery and release. Physicians are allowed to
   visualize this complicated process through the hysteroscopic equipment provided by Defendants.
- 5

6

7

25. After placement of the coils in the fallopian tubes by Defendants' disposable delivery system, the micro-inserts expand upon release and anchor into the fallopian tubes. The PET fibers in the coil allegedly elicit tissue growth blocking off the fallopian tubes.

26. The coils are alleged to remain securely in place in the fallopian tubes for the life of the consumer and do not migrate.

After three months following the device being implanted, patients are to receive a
 "Confirmation" test to determine that the micro-inserts are in the correct location and that the tissue
 has created a complete occlusion. This is known as a hystersalpingogram ("HSG Test" or
 "Confirmation test").

Regardless of the Confirmation Test, Defendants also warrant that Essure® allows for
 visual confirmation of each insert's proper placement during the procedure.

15 29. Essure® was designed, manufactured, and marketed to be used by gynecologists
16 throughout the world, as a "quick and easy" outpatient procedure and without general anesthesia.

17

18

19

#### B. <u>Evolution Of Essure®</u>

30. Essure® was first designed and manufactured by Conceptus, Inc. ("Conceptus").

31. Conceptus and Bayer merged on or about April 28, 2013.

20 32. For purpose of this lawsuit, Conceptus and Bayer are one and the same.

21 33. Essure®, a Class III medical device, is now manufactured, sold, distributed, marketed,
 22 and promoted by Defendants.

23

34. Defendants also trained physicians on how to use its device and other hysteroscopic equipment, including Plaintiff's implanting physician.

24 25

35. Prior to the sale of Conceptus to Bayer, Conceptus obtained CPMA for Essure®.

36. By way of background, Premarket Approval ("PMA") is the FDA process of scientific
and regulatory review to evaluate the safety and effectiveness of Class III medical devices.
According to the FDA, Class III devices are those that support or sustain human life, are of

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 6 of 32

substantial importance in preventing impairment of human health, or which present a potential, 1 unreasonable risk of illness or injury. 2

37. PMA is a stringent type of device marketing application required by FDA. The 3 applicant must receive FDA approval of its PMA application prior to marketing the device. PMA 4 approval is based on a determination by the FDA. 5

6

7

38. An approved PMA is, in effect, a private license granting the application (or owner) permission to market the device.

39. FDA regulations provide 180 days to review the PMA and make a determination. In 8 reality, the review time is normally longer. Before approving or denying a PMA the appropriate 9 FDA advisory committee may review the PMA at a public meeting and provide FDA with the 10 committee's recommendation on whether FDA should approve the submission.

11

According to the FDA, a class III device that **fails to meet the CPMA** requirements is 40. 12 considered to be adulterated under section 501(f) of the Federal Food, Drug and Cosmetic Act 13 ("FD&C Act") and cannot be marketed.

14 41. Regarding the Premarket Approval Process, devices can either be "approved," 15 "conditionally approved," or "not approved."

16 42. Essure® was "conditionally approved" or in other words, had only CPMA not 17 outright PMA, the "gold standard."

18 43. In the CPMA Order issued by the FDA, the FDA expressly stated, "Failure to comply with the conditions of approval invalidated this approval order." The following were the 19 conditions of approval: 20

"Effectiveness of Essure is established by annually reporting on the 745 (a) 21 women who took part in clinical tests." 22

"Successful bilateral placement of Essure is documented for newly trained (b) 23 physicians." 24

"Within 10 days after [Defendant] received knowledge of any adverse reaction (c) 25 to report the matter to the FDA." 26

(d) "Report to the FDA whenever it received information from any source that 27 reasonably suggested that the device may have caused or contributed to a serious injury,"

# Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 7 of 32

1		(e)	Warranties are truthful, accurate and not misleading.				
2		(f)	Warranties are consistent with applicable Federal and State law.				
3	44.	Altho	bugh failure to comply with just one of the conditions invalidated the CPMA				
4	Order, Defend	dants fa	ailed to comply with several conditions; thereby invalidating the CPMA pursuant				
5	to the very language of the CPMA order. Specifically:						
6		(a)	Defendants failed to timely provide the FDA with reports after 12 months, 18				
7	months and th	nen a fi	nal report. All reports failed to meet the respective deadlines.				
8		(b)	Defendants failed to document successful placement of Essure® concealing				
9	the failure rate	es.					
10		(c)	Defendants failed to notice the FDA of several adverse reactions and actively				
	concealed the	same.	Most egregiously, Defendants <i>failed to report eight (8) perforations</i> which				
11	occurred as a	result	of Essure® and was cited for the same by the FDA via Form 483 <sup>1</sup> .				
12		(d)	Defendants failed to report to the FDA information it received that reasonably				
13	suggested tha	t the d	evice may have caused or contributed to a serious injury thereby concealing the				
14	injuries. Aga	in, De	fendants failed to report eight (8) perforations which occurred as a result of				
15	Essure® to th	e FDA	as evidenced in Form 483.				
16		(e)	As outlined in "Facts and Warranties" infra, Defendants' warranties were not				
17	truthful, accur	rate, an	id not misleading.				
18		(f)	Defendants' warranties were not consistent with applicable Federal and State				
19	law.						
20	45.	By fa	iling to comply with several CPMA conditions, Essure® is also considered to be				
21	an "adulterate	ed" dev	vice under section 501(f) of the FD&C Act and cannot be marketed per the				
22	<b>FDA</b> . Howev	ver, De	fendants continued to market the product to Plaintiff.				
23	46.	The (	CPMA also required Defendants to comply with Sections 502(q) and (r) of the				
24	FD&C Act which prohibits Defendants from offering Essure® "for sale in any State, if its						
25	advertising is false or misleading."						
26							
27							
28			irm management at the conclusion of inspection when an FDA investigator has observed any the FD&C Act rendering the device "adulterated."				

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 8 of 32

- 47. Defendants violated Sections 502(q) and (r) by falsely and misleadingly advertising
   the product as described below under "Facts and Warranties." However, Defendants continued to
   sell its product against the CPMA with misleading and false advertising.
- 4

5

6

7

8

48. Lastly, per the FDA, "a PMA may be sold to another company" however "the sponsor **must submit a PMA amendment** to notify the FDA of the new owner... The... supplement should include: the effective date of the ownership transfer; a statement of the new owner's commitment to comply with all the conditions of approval applicable to the PMA; and either a statement that the new owner has a complete copy of the PMA including all amendment, supplements, and reports or a request for a copy from the FDA files."

9 10

49. There were 36 PMA supplements filed with the FDA in regard to Essure® (P020014). None of the PMA supplements included notification of the new owner (Bayer).

In short, notwithstanding the fact that Plaintiff's claims fall outside the purview of the
 MDA, (1) the CPMA is invalid per the FDA; (2) Essure® is considered an "adulterated" product
 that cannot be marketed or sold per the FDA; and (3) the invalid CPMA was not properly transferred
 to Bayer and, therefore, Defendants does not have any form of PMA for Essure®.

15

### C. Defendant's Training, Entrustment And Distribution Plan

16 51. Defendants (1) failed to adequately train the implanting physician on how to use its
17 delivery system and the hysteroscopic equipment manufactured by a third party; (2) provided
18 specialized hysteroscopic equipment manufactured by a third party; and (3) created an unreasonably
19 dangerous distribution plan, all of which were aimed at capitalizing on and monopolizing the birth
20 control market at the expense of Plaintiff's safety and well-being.

21

22

23

52. Because Essure® was the first device of its kind, the implanting physician was **trained by Defendants** on how to properly insert the micro-inserts using the disposable delivery system and was given hysteroscopic equipment by Defendants.

- 53. In order to capture the market, Defendants independently undertook a duty of training
   physicians, including the implanting physician, on how to properly use (1) its own mechanism of
   delivery and (2) the specialized hysteroscopic equipment manufactured by a third party.
- 27
- 28

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 9 of 32

- 1 54. Regarding Essure®, Defendants' Senior Director of Global Professional Education stated "training is the key factor when clinicians choose a new procedure" and "For the Essure® 2 procedure, the patient is **not under anesthesia**, therefore a **skilled approach is crucial**." 3
- In fact, because gynecologists and Plaintiff's implanting physician were unfamiliar 55. 4 with the device and how to deliver it, Defendants (1) created a "Physician Training Manual"; (2) created a simulator called EssureSim; (3) organized limited training courses where Defendants 6 observed physicians until Defendants believed they were competent; (4) created Essure® Procedure Equipment Supplies Checklists; and (5) represented to Plaintiff that "Physicians must be signed-off 8 to perform Essure procedures." 9
- 56. Defendants provided no training to the implanting physician on how to *remove* 10 Essure<sup>®</sup> should it migrate or cause serious medical conditions necessitating its removal.
- 11 57. Defendants also kept training records on all physicians "signed-off to perform Essure 12 procedures."
- 13 58. In order to sell its product and because the implanting physician did not have access to 14 the expensive hysteroscopic equipment, Defendants provided the implanting physician with 15 hysteroscopic equipment which, although is not a part of Essure<sup>®</sup>, is needed to implant Essure<sup>®</sup>. 16 The entrustment of this equipment is not part of any CPMA.
- 17 59. Defendants entered into agreements with Johnson & Johnson Co., Olympus America, Inc., Richard Wolf Medical Instruments Corp., and Karl Storz Endoscopy, America, Inc., (1) to 18 obtain specialized hysteroscopic equipment to then give to physicians and (2) to increase its sales 19 force to promote Essure®. 20
- 60. According to Defendants, these agreements allowed Defendants to "gain market 21 presence [...] and expend [...] market opportunity by driving adoption among a group of physicians." 22
- 23

24

5

- In regard to the entrustment of such specialized equipment, Defendants admitted: "We 61. cannot be certain how successful these programs will be, if at all."
- Defendants "handed out" this equipment to unqualified physicians, including 62. 25 Plaintiff's implanting physician, in an effort to sell its product. 26
- 27
- 28

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 10 of 32

1 63. Defendants knew or failed to recognize that the implanting physician was not qualified to use such specialized equipment yet provided the equipment to the unqualified implanting 2 physician in order to capture the market. 3

4

5

6

7

In return for providing the hysteroscopic equipment, Defendants required that the 64 implanting physician purchase two Essure® "kits" per month. This was part of Defendants' unreasonably dangerous and negligent distribution plan aimed solely at capturing the market with reckless disregard for the safety of the public and Plaintiff.

65. Defendants' distribution plan included requiring the implanting physician to purchase 8 two (2) Essure® "kits" per month, regardless of whether he or she used them or not. This 9 distribution plan created an environment which induced the implanting physician to "push" Essure® 10 and implant the same into Plaintiff.

11 In short, Defendants used the expensive hysteroscopic equipment to induce the 66. 12 implanting physician into an agreement as "bait." Once the implanting physician "took the bait," he 13 was required to purchase 2 Essure® "kits" per month, regardless of whether he sold any Essure® 14 "kits."

15 67. This was an unreasonably dangerous distribution scheme as it compelled the 16 implanting physician to sell two (2) devices per month at the expense of Plaintiff's safety and well-17 being.

18 68. Defendants' distribution plan also included (1) negligently distributing Essure® against FDA order and sections 501(f), 502(q) and (r) of the FD&C Act by marketing and selling an 19 adulterated product; (2) the promotion of Essure® through representatives of the hysteroscopic 20 equipment manufacturers, who were not adequately trained nor had sufficient knowledge regarding 21 Essure<sup>®</sup>; (3) failing to report and actively concealing eight perforations which occurred as a result of 22 Essure<sup>®</sup>; (4) erroneously using non-conforming material in the manufacturing of Essure<sup>®</sup>; (5) failing 23 to use pre-sterile and post-sterile cages; (6) manufacturing Essure® at an unlicensed facility and (7) 24 manufacturing Essure® for three years without a license to do so. 25

26

69. In short, Defendants (1) failed to adequately train the physicians on how to use its delivery system and the hysteroscopic equipment manufactured by a third party; (2) provided 27 specialized hysteroscopic equipment to implanting physicians who were not qualified to use the

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 11 of 32

same; and (3) created an unreasonably dangerous distribution plan, all of which were aimed at
 capitalizing and monopolizing on the birth control market.

Unfortunately, this was done at the expense of Plaintiff's safety.

3

4

10

70.

#### D. <u>Plaintiff's History</u>

71. Prior to the operation, Plaintiff went to the implanting physician to discuss options for
 permanent sterilization. The implanting physician recommended that Plaintiff have Essure®
 implanted in her fallopian tubes instead of a standard tubal ligation procedure.

72. In or around July 30, 2013, Plaintiff returned to the implanting physician for the
Essure® procedure. The implanting physician implanted the Essure® coils into both her left and
right fallopian tubes.

73. After the procedure to implant the device in 2013, Plaintiff started experiencing severe
 constant daily pain. Since the device was implanted, Plaintiff has also suffered from constant pain,
 and mental and emotional anguish.

13 74. Plaintiff had a total hysterectomy on January 7, 2015 to control the excruciating pain
 14 caused by the Essure device.

15 75. Plaintiff did not become aware that Essure was the cause of her above-described
16 physical, emotional, and medical problems until 2015 when she learned, through internet research, of
17 other women having similar issues.

76. Plaintiff did not have knowledge of facts that would lead a reasonable, prudent person
to make inquiry to discover Defendants' tortuous conduct. Under appropriate application of the
discovery rule, Plaintiff's suit was filed well within the applicable statutory limitations period.

77. Additionally, Defendants' fraudulent concealment of the relevant facts as described *infra* toll any relevant statutes of limitations. Most egregiously, Defendant was not only actively and
fraudulently concealing adverse reports of migrations and perforations from Plaintiff, but also from
the FDA. This active concealment is not mere allegation, but evidenced by FDA findings and its
citations to Defendant for failing to report eight (8) perforations.

26

E. <u>Facts And Warranties</u>

78. First, Defendants negligently trained physicians, including the implanting physician,
 on how to use its device and in hysteroscopic procedures.

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 12 of 32

79. The skills needed to place the micro-inserts as recognized by the FDA panel "are way
 beyond the usual gynecologist."

80. Accordingly, Defendants went out and attempted to train the implanting physician on
(1) how to use its device and (2) in hysteroscopy. Defendants (1) created a "Physician Training
Manual"; (2) created a simulator called EssureSim; (3) organized limited training courses-where
Defendants observed physicians until Defendants believed they were competent; (4) created Essure®
Procedure Equipment Supplies Checklists; and (5) represented to Plaintiff that "Physicians must be
signed-off to perform Essure procedure." Defendants had no experience in training others in
hysteroscopy.

81. Defendants failed to adequately train Plaintiff's implanting physicians and provided
 hysteroscopic equipment to the implanting physician who was not qualified to use such complicated
 equipment.

12 82. A key study found that a learning curve for this hysteroscopic procedure was seen for
 13 procedure time, but not for successful placement, pain, and complication rates, evidencing that
 14 Defendants' training methods were failing<sup>2</sup>.

15 83. Second, Defendants provided hysteroscopic equipment to the implanting physician
16 who was not competent to use such device. Defendants knew the implanting physician was not
17 competent to use such sophisticated equipment, yet provided the equipment anyway in order to sell
18 its product.

19 84. Third, Defendants' distribution plan of requiring the implanting physician to purchase
20 two (2) Essure® kits a month, was an unreasonably dangerous plan as it compelled the implanting
21 physician to insist that Essure® be used in Plaintiff.

85. Defendants' distribution plan also included (1) negligently distributing Essure®
against FDA order and sections 501(f), 502(q) and (r) of the FD&C Act by marketing and selling an
adulterated product; (2) the promotion of Essure® through representatives of the hysteroscopic
equipment manufacturers, who were not adequately trained nor had sufficient knowledge regarding
Essure®; (3) failing to report and actively concealing (8) perforations which occurred as a result of
Essure®; (4) erroneously using non-conforming material in the manufacturing of Essure®; (5) failing

- ,

<sup>28 &</sup>lt;sup>2</sup> Learning Curve of Hysteroscopic Placement of Tubal Sterilization Micro-Inserts, US National Library of Medicine, Janse, JA.

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 13 of 32

to use pre-sterile and post sterile cages; (6) manufacturing Essure® at an unlicensed facility and (7) 1 manufacturing Essure® for three years without a license to do so. 2 86. Lastly, Plaintiff relied on the following warranties by Defendants and/or its agents, 3 outlined in the subsequent Paragraphs: 4 **Website Warranties** a. 5 87. Defendants marketed on its website the following: 6 (a) "Only FDA approved female sterilization procedure to have zero pregnancies 7 in the clinical trials." However, there were actually four pregnancies during the clinical trials and 8 five pregnancies during the first year of commercial experience. Defendants concealed this 9 information from Plaintiff. 10 "There were Zero pregnancies in the clinical trials." However, there were (b) 11 actually four pregnancies during the clinical trials and five pregnancies during the first year of 12 commercial experience. Defendants concealed this information from Plaintiff. 13 (c) "Physicians must be signed-off to perform Essure procedure." However, 14 Defendants failed to adequately train the implanting physician and "signed-off" on the implanting 15 physician who did not have the requisite training. Defendants concealed this information from 16 Plaintiff. 17 (d) "Surgery-free." However, Essure® is not "surgery-free," rather laparoscopic surgery is not required. All Essure® procedures are done under hysteroscopy, which is a surgical 18 procedure. 19 (e) "Worry free: Once your doctor confirms that your tubes are blocked, you 20 never have to worry about unplanned pregnancy." However, several pregnancies have been reported 21 subsequent to confirmation. Defendants concealed this information from Plaintiff. However, from 22 1997 to 2005, 64 pregnancies were reported to Defendants. Defendants concealed this information 23 from Plaintiff. However, Adverse Event Report ESS 205 dated 10/3/2006 evidences a pregnancy 24 after the three month Confirmation Test was confirmed. Defendants concealed this information from 25 Plaintiff. However, there have been over 30 pregnancies after "doctors confirmed the tubes were 26 blocked." However, women who have Essure® have 10 times greater risk of pregnancy after one 27 28 13

year than those who use laparoscopic sterilization. At ten years, the risk of pregnancy is almost four
 (4) times greater<sup>3</sup>.

(f) "Essure is the most effective permanent birth control available-even more
effective than tying your tubes or a vasectomy." Yet, Defendants' SEC filings, Form 10-K show
that Defendants never did a comparison to a vasectomy or tubal ligation. Defendants stated, "We
did not conduct a clinical trial to compare the Essure procedure to laparoscopic tubal ligation."
Defendants concealed this information from Plaintiff. In fact, women who have Essure® have 10
times greater risk of pregnancy after one year than those who use laparoscopic sterilization. At ten
years, the risk of pregnancy is almost 4 times greater<sup>4</sup>.

 (g) "Correct placement...is performed easily because of the design of the microinsert." However, Defendants admitted that placement of the device requires a "skilled approach" and even admitted that their own experts in hysteroscopy (as compared to general gynecologists not on the same level as an expert hysteroscopist) failed to place the micro-inserts in 1 out of 7 clinical participants. Defendants concealed this information from Plaintiff.

(h) "an Essure trained doctor inserts spring-like coils, called micro-inserts..."
However, the implanting physician who implanted the device was not adequately trained.
Defendants concealed this information from Plaintiff.

(i) "the Essure training program is a comprehensive course designed to provide
information and skills necessary to select appropriate patients, perform competent procedures and
manage technical issues related to the placement of Essure micro-inserts for permanent birth
control." However, Defendants failed to adequately train the implanting physician. Defendants
concealed this information from Plaintiff.

- (j) "In order to be trained in Essure you must be a skilled operative hysteroscopist.
  You will find the procedure easier to learn if you are already proficient in operative hysteroscopy
  and management of the awake patient. If your skills are minimal or out of date, you should attend a
  hysteroscopy course before learning Essure." However, Defendants "signed off" on the implanting
- 26

COMPLAINT FOR DAMAGES AND DEMAND FOR JURY TRIAL

<sup>27 &</sup>lt;sup>3</sup> *Probability of Pregnancy After Sterilization: A Comparison Of Hysteroscopic Versus Laparoscopic Sterilization,* Gariepy, Aileen. Medical Publication "Contraception." Elsevier 2014.

 <sup>&</sup>lt;sup>4</sup> Probability of Pregnancy After Sterilization: A Comparison Of Hysteroscopic Versus Laparoscopic Sterilization, Gariepy, Aileen.
 28 Medical Publication "Contraception." Elsevier 2014.

### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 15 of 32

1	physician who was not a skilled operative hysteroscopist, in order to monopolize and capture the
2	market, including the implanting physician. Defendants concealed this information from Plaintiff.
3	(k) <i>"Essure is a surgery-free permanent birth control."</i> However, Essure® is not
4	permanent as the coils migrate, perforate organs and are expelled by the body.
5	b. <u>Advertisement Warranties</u>
6	88. Defendants advertised:
7	(a) "Zero pregnancies" in its clinical and pivotal trials. However, there were at
8	least four pregnancies. Defendants concealed this information from Plaintiff.
9	(b) In order to be identified as a qualified Essure® physician, a minimum of one
10	Essure® procedure must be performed every 6-8 weeks. However, Defendants "signed off" on
	"Essure physicians" who did not perform the procedure every 6-8 weeks, including the implanting
11	physician. Defendants concealed this information from Plaintiff.
12	c. <u>Fact Sheet Warranties</u>
13	89. Defendants represented in its Fact Sheet:
14	(a) Data from two clinical studies show that 99 percent of the women who had the
15	Essure® procedure rated their long-term comfort with the micro-inserts as 'good,' 'very good' or
16	'excellent'." However, the actual choices given to the clinical participants were 'poor,' 'very good,'
17	or 'excellent'. Defendants concealed this information from Plaintiff.
18	d. <u>Warranties By Agents</u>
19	90. Defendants' Senior Director of Global Professional Education represented to the
20	public that "For the Essure procedure, the patient is not under anesthesia, therefore a skilled
21	approach is crucial." Yet, Defendants also claims that "Correct placementis performed easily
22	because of the design of the micro-insert"
23	91. Defendants' CEO stated: "Essure allows you to push away the constant worry about
24	an unplanned pregnancy that's our message and that's our theme." However, there were actually
25	four pregnancies during the clinical trials and five pregnancies during the first year of commercial
26	experience. Defendants concealed this information from Plaintiff. However, between 1997-2005,
27	64 pregnancies were reported to Defendants. Defendants concealed this information from Plaintiff.
27 28	However, there have been over 30 pregnancies after "doctors confirmed the tubes were blocked."
2.01	15

1

2

#### e. <u>Marketing Warranties</u>

92. Defendants marketed with commercial stating:

3

4

6

7

8

9

(a) *Essure bas been in use for over 5 years*. However, Essure *was only in use for 4 years at the time of the warranties.* Defendants concealed this information from Plaintiff.

5

(b) "The non-surgical" permanent birth control for woman." However, the procedure is most commonly done with surgery. Defendants concealed this information from Plaintiff. However, Essure® is not permanent as the coils migrate, perforate organs and are expelled by the body. However, all Essure® procedures are done under hysteroscopy, which is a surgical procedure.

93. Defendants created a fake blog entitled "Diary of a Decision" in order to induce Plaintiff to use Essure®. Defendants created a fictitious person, names "Judy" who pretended to have had the procedure and answered questions from Plaintiff. However, "Judy" never had the procedure as represented and was actually Debbie Donovan. Defendants concealed this information from Plaintiff.

14 94. Defendants warranted that Essure® "allows for visual confirmation of each insert's
15 proper placement both during the procedure and during the Essure Confirmation Test." However,
16 Essure® does not allow for visual confirmation of proper placement during the procedure evidenced
17 by the fact that three micro-inserts were placed into Plaintiff.

18

19

#### f. <u>Brochure Warranties</u>

95. Defendants' Essure® brochure warrants:

"Worry free." However, Defendants actively concealed and failed to report (a) 20 8 perforations which occurred as a result of Essure® to the FDA evidence in a Form 483 issued 21 by the FDA to Defendants. Defendants actively concealed this from Plaintiff. See Most egregiously, 22 Defendants were issued another Form 483 when it "erroneously used non-conforming material." 23 Defendants actively concealed this and were issued an additional Form 483 for "failing to adequately 24 document the situation." Defendants actively concealed this from Plaintiff. However, Defendants' 25 facility was also issued a notice of violation as it "no longer uses pre-sterile and post-sterile 26 cages." Defendants actively concealed this from Plaintiff. However, Defendants were also issued a 27 notice of violation when "it failed to obtain a valid license...prior to manufacturing medical 28

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 17 of 32

devices." Defendants were manufacturing devices for three years without a license. Defendants 1 actively concealed this from Plaintiff. However, Defendants were also issued a notice of violation as 2 it was manufacturing medical devices from 2005 at an unlicensed facility. Defendants actively 3 concealed this from Plaintiff. 4

5

"The Essure inserts stay secure, forming a long protective barrier against (b) pregnancy. They also remain visible outside your tubes, so your doctor can confirm that they're 6 properly in place." However, the micro-inserts do not remain secure but migrate and expelled by the 7 body. Defendants actively concealed this information from Plaintiff. However, Defendants actively 8 concealed and failed to report 8 perforations which occurred as a result of Essure® to the FDA 9 as evidenced in Form 483 issued to Defendants by the FDA.

10

(c) "The Essure inserts are made from the same trusted, silicone free material 11 used in heart stents." However, the micro-inserts are not made from the same material as heart stents. 12 Specifically, the micro-inserts are made of PET fibers which trigger inflammation and scar tissue 13 growth. Heart stents do not elicit tissue growth. Defendants actively concealed this from Plaintiff. 14 PET fibers are not designed or manufactured for use in human implantation. Moreover, Defendants 15 also warranted: "the long-term nature of the tissue response to the Essure micro-insert is not known." 16 However, the PET fibers are made of the same materials as the PVT material in vaginal meshes 17 which have a high rate of expulsion. Most egregiously, Defendants were issued another Form 483 when they "erroneously used non-conforming material." Defendants actively concealed this and 18 were issued another Form 483 for "failing to adequately document the situation." 19

"Surgery-free." However, all Essure® procedures are done under (d) 20 hysteroscopy, which is a surgical procedure. 21

"Anesthesia-free." However, Essure® is not "anesthesia-free", rather (e) 22 anesthesia is not required. 23

Step Two: "pregnancy cannot occur"; Step Three: The Confirmation. (f)24 However, Defendants also state that it is only after "The Confirmation" that pregnancy cannot occur, 25 *i.e.* the complete opposite of what is warranted in the brochure. However, Adverse Event Report 26 ESS 205 dated 10/3/2006 evidences a pregnancy after the three month confirmation test was 27 confirmed. However, between 1997–2005, 64 pregnancies were reported to Defendants. 28

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 18 of 32

Defendants concealed this information from Plaintiff. However, there have been over 30 pregnancies
 after "doctors confirmed the tubes were blocked." However, there have been incidents where the
 micro-inserts were expelled from the body even after the Confirmation Test<sup>6</sup>.

4 (g) "Essure eliminates the risks, discomfort, and recovery time associated with
5 surgical procedures." However, Essure® is not "surgery-free". Rather laparoscopic surgery is not
6 required.

7 96. The PET fibers are what cause the tissue growth. However, during the PMA meeting
with the FDA, Defendants represented that the trauma caused by the expanding coil striking the
fallopian tubes is what caused the inflammatory response of the tissue. Defendants concealed this
information from Plaintiff.

**Essure® Booklet Warranties** 

- 10
- 11

19

20

97.

Defendants' Essure® booklet warrants:

g.

(a) "This viewable portion of the micro-insert serves to verify placement and does
 not irritate the lining of the uterus." However, the device does irritate the uterus. Defendants
 concealed this information from Plaintiff. However, Defendants actively concealed and <u>failed to</u>
 <u>report 8 perforations</u> which occurred as a result of Essure® to the FDA as evidence in Form
 483.

(b) *"There was no cutting, no pain, no scars..."* However, Plaintiff has
experienced pain as a result of Essure<sup>®</sup>. Defendants concealed this information from Plaintiff.

h. Data Warranties

98. Summary of Safety and Effectiveness Data states:

(a) "The Essure System provides permanent birth control without invasive surgery
 or general anesthesia, and their associated risks." However, Essure® is not "surgery-free" or
 "anesthesia-free," rather laparoscopic surgery and anesthesia are not required.

(b) "In addition to the above benefits, none of the women in the Essure clinical
trials became pregnant." However, there were at least four pregnancies during the clinical trials.
Defendants concealed this information from Plaintiff.

- 27
- 28

 (c) "Namely, the Essure system is delivered hysteroscopically without general anesthesia." However, Essure® is not "surgery-free" or "anesthesia-free," rather laparoscopic surgery and anesthesia are not required.

4

### i. <u>PMA Supplement</u>

99. Defendants represented to Plaintiff that it was the expanding coil and tissue growth
which caused the coil to be attached to the tube, not any type of coating. Yet, in Supplement 18,
Defendants represented that "A doctor placed the coil at the uterine-fallopian tube junction, where its
coating caused it be attached to the tube." The coating is a hydrophilic polymer coating produced
by AST Products, Inc. Defendants actively concealed this from Plaintiff.

10

#### j. <u>SEC Filings</u>

100. Defendants warranted that the Essure® system has "no risks" for patients because...
 the Essure® system does not involve the use of radiofrequency energy. At the same time,
 Defendants also states that there are limited risks with Essure®.

13 101. "Our Mountain View, California facility underwent an International Organization for
14 Standardization ("ISO") inspection in September 2011 which resulted in continuing approval and
15 ISO certification through May 2013. In December 2010/January 2011, we underwent an FDA audit;
16 all findings from the audit were satisfactorily addressed." However, Defendants actively concealed
17 the following:

18 (a) However, Defendants' site has been inspected 7 times since 06/25—
19 07/09/2002. The most recent FDA audit occurred on 05/30—6/26/2013. The FDA has issued 4 Form
20 483 inspectional observations.

(b) However, Defendants actively concealed and failed to report 8 perforations
 which occurred as a result of Essure® to the FDA as evidenced in Form 483.

(c) Most egregiously, Defendants were issued another Form 483 when they
 *"erroneously used non-conforming material."* Defendants actively concealed this and were issued
 another Form 483 for "failing to adequately document the situation."

(d) However, Defendants' facility was also issued a violation as it <u>"no longer</u>
 uses pre-sterile and post-sterile cages."

# Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 20 of 32

1	(e) However, Defendants also was issued a violation when it <u>"failed to obtain a</u>
2	valid licenseprior to manufacturing medical devices." Defendants were manufacturing devices
3	for three years without a license.
4	102. The subsequent negligence claims are not products liability causes of action. The
5	claims have nothing to do with the Essure® product or its invalid CPMA, but rather (1) the
6	failure of Defendants to adequately train and instruct the implanting physician and/or (2) the fact that
7	Defendants provided the implanting physician, who was not a hysteroscopist, with hysteroscopic
8	equipment in order to sell their product and/or (3) Defendants' unreasonably dangerous distribution
9	of Essure®.
10	FIRST CAUSE OF ACTION
10	MANUFACTURING DEFECT
	103. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set
12	forth herein and alleges as follows:
13	104. At all relevant times, Defendants were engaged in the business of selling Essure® in
14	the states of California and Arizona.
15	105. The Essure® manufactured, designed, formulated, tested, packaged, labeled,
16	produced, created, made, constructed, assembled, marketed, advertised, distributed, and sold by
17	Defendants was expected to, and did, reach Plaintiff without substantial change in the condition in
18	which it was sold.
19	106. Defendants have introduced a product into the stream of commerce which is
20	dangerous and unsafe in that the harm of Essure® outweighs any benefit derived there from. The
21	unreasonably dangerous nature of Essure® caused serious harm to Plaintiff.
22	107. Defendants manufactured, marketed, promoted and sold a product that was not
23	merchantable and/or reasonably suited to the use intended, and its condition when sold was the
24	proximate cause of the injured sustained by the Plaintiff and Defendants placed Essure® into the
25	stream of commerce with wanton and reckless disregard for the public safety.
26	108. As a direct and proximate result of Plaintiff's use of Essure®, she was forced to
27	undergo a surgical procedure to control the heavy bleeding caused by the Essure® coils.
28	
	20

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 21 of 32

1 109. Defendants knew and, in fact, advertised and promoted the use of Essure® despite their failure to test or otherwise determine the safety and efficacy of such use. As a direct and 2 proximate result of the Defendants' advertising and widespread promotional activity, physicians 3 began commonly promoting this product as a safe and effective contraceptive. 4

5

6

7

8

110. Despite the fact that evidence existed that the use of Essure® was dangerous and likely to place users at serious risk to their health, Defendants failed to disclose and warn of the health hazards and risks associated with Essure® and in fact acted to deceive the medical community and public at large, including all potential users of Essure®, by promoting it as safe and effective.

111. Defendants knew or should known that physicians and other healthcare providers 9 began commonly prescribing this product as a safe and effective contraceptive despite its lack of 10 efficacy and potential for serious permanent side effects.

11

There are contraceptives and surgical procedures on the market with safer alternative 112. 12 designs in that they provide equal or greater efficacy and far less risk.

13

113. As a direct and proximate result of one or more of these wrongful acts or omissions of 14 the Defendants, Plaintiff suffered profound injuries, required medical treatment, and incurred and 15 continues to incur medical and hospital expenses.

16 WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory, 17 and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as the court deems appropriate pursuant to the common law and statutory law. 18

19

20

### SECOND CAUSE OF ACTION

#### **DESIGN DEFECT**

114. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set 21 forth herein and further alleges as follows: 22

Defendants were and are engaged in the business of selling Essure® in the States of 115. 23 California and Arizona. 24

116. The Essure® manufactured, designed, formulated, tested, packaged, labeled, 25 produced, created, made, constructed, assembled, marketed, advertised, distributed and sold by 26 Defendants was expected to, and did, reach Plaintiff without substantial change in the condition in 27 which it was sold.

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 22 of 32

1 117. The foreseeable risks associated with the design or formulation of the Essure® is more
 2 dangerous than a reasonably prudent consumer would expect when used in an intended or reasonably
 3 foreseeable manner.

- 118. Defendants manufactured, designed, formulated, tested, packaged, labeled, produced,
  created, made, constructed, assembled, marketed, advertised, distributed and sold a product that was
  not merchantable and/or reasonably suited to the use intended, and its condition when sold was the
  proximate cause of the injuries sustained by the Plaintiff.
- As a direct and proximate cause of Plaintiff's use of Essure®, she was forced to
   undergo medical procedures to manage her symptoms, developed severe pain, suffers from migraines
   and has undergone numerous procedures.
- 10
   120. Defendants placed Essure® into the stream of commerce with wanton and reckless
   disregard for the public safety.
- 12 121. Defendants knew or should have known that physicians and other healthcare providers
   13 began commonly prescribing this product as a safe and effective contraceptive despite its lack of
   14 efficacy and potential for serious permanent side effects.
- 15 122. There are contraceptives on the market with safer alternative designs in that they
  16 provide equal or greater efficacy and far less risk.
- 17 123. As a direct and proximate result of one or more of these wrongful acts or omissions of
  18 Defendants, Plaintiff suffered profound injuries, required medical treatment, and incurred and
  19 continues to incur medical and hospital expenses.
- WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory
   and punitive damages, together with interest, cost of suit, attorneys' fees and all such other relief as
   the Court deems appropriate pursuant to the common law and statutory law.
- 23

24

### THIRD CAUSE OF ACTION

#### NEGLIGENCE

- 124. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set
   forth herein and further alleges as follows:
- 27 125. Upon information and belief, Defendants failed to use reasonable care in designing Essure® in that they:
- 28

1	a. failed to properly and thoroughly test Essure® before releasing the system to					
2	market;					
3	b. failed to properly and thoroughly analyze the data resulting from the					
4	premarketing tests of Essure®;					
5	c. failed to conduct sufficient post-market testing and surveillance of Essure®;					
6	d. designed, manufactured, marketed, advertised, distributed, and sold Essure® to					
7	consumers, including Plaintiff, without an adequate warning of the significant and dangerous risks of					
8	Essure® and without proper instructions to avoid the harm which could foreseeably occur as a result					
9	of using the system;					
10	e. failed to exercise due care when advertising and promoting Essure®; and,					
	f. negligently continued to manufacture, market, advertise and distribute					
11	Essure® after Defendants knew or should have known of its adverse effects.					
12	126. A reasonable manufacturer would or should have known that the risks created by					
13	Essure® are unreasonably greater than that of other contraceptives and that Essure® has no clinical					
14	benefit over such other contraceptives that compensates in whole or part for the increased risk.					
15	127. As a direct and proximate result of one or more of these wrongful acts or omissions of					
16	Defendants, Plaintiff suffered profound injuries, required medical treatment, and incurred and					
17	continues to incur medical and hospital expenses.					
18	FOURTH CAUSE OF ACTION					
19	FAILURE TO WARN					
20	128. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set					
21	forth herein and further alleges as follows:					
22	129. Essure® is a defective and therefore an unreasonably dangerous product, because its					
23	labeling fails to adequately warn consumers and prescribers of, among other things, the risk of					
24	migration of the product post-insertion, uterine perforation post-insertion, or the possibility that					
25	device complications such as migration and perforation may cause abscesses, infections, require					
26	surgery for removal and/or may necessitate a hysterectomy, oophorectomy, salpingectomy, uterine					
20 27	ablation, and cause other complications.					
27 28						
Ζ.Δ	23					

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 24 of 32

1 130. Defendants manufactured, designed, formulated, tested, packaged, labeled, produced,
 2 created, made, constructed, assembled, marketed, advertised, distributed and sold and otherwise
 3 released into the stream of commerce Essure®, and in the course of same, directly advertised or
 4 marketed the product to consumers or persons responsible for consumers, and therefore had a duty to
 5 warn of the risks associated with the use of Essure®.

6

7

8

9

10

131. Essure® was under the exclusive control of Defendants and was unaccompanied by appropriate warnings regarding all of the risks associated with its use. The warnings given did not accurately reflect the risk, incidence, symptoms, scope or severity of such injuries to the consumer or physicians. The promotional activities of Defendants further diluted or minimized the warnings given with the product.

132. Defendants downplayed the serious and dangerous side effects of Essure® to
 encourage sales of the product; consequently, Defendants placed its profits above its customers'
 safety.

13 133. Essure® was defective and unreasonably dangerous when it left the possession of
14 Defendants in that it contained warnings insufficient to alert Plaintiff to the dangerous risks and
15 reactions associated with it. Even though Defendants knew or should have known of the risks
16 associated with Essure®, they still failed to provide warnings that accurately reflected the signs,
17 symptoms, incident, scope, or severity of the risks associated with the product.

18 134. Plaintiff used Essure® as intended and as indicated by the package labeling or in a
19 reasonably foreseeable manner.

20 135. Plaintiff could not have discovered any defect in Essure® through the exercise of
 21 reasonable care.

136. Defendants, as manufacturers of pharmaceutical drugs and products, are held to the
level of knowledge of an expert in the field and, further, Defendants had knowledge of the dangerous
risks and side effects of Essure<sup>®</sup>.

137. Plaintiff did not have the same knowledge as Defendants and no adequate warning
 was communicated to her physician(s).

138. Defendants had a continuing duty to warn consumers, including Plaintiff and her
 physicians, and the medical community of the dangers associated with its use, Defendants breached

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 25 of 32

their duty. Under Ninth Circuit federal law, Plaintiff's claims for breach of failure to warn after FDA 1 approval are not preempted by the Medical Device Act ("MDA"). Stengel v. Medtronic Incorporated, 2 704 F.3d 1224 (9th Cir. 2013). 3

Although Defendants knew, or were reckless in not knowing, of the defective nature 139. 4 of Essure<sup>®</sup>, they continued to manufacture, design, formulate, test, package, label, produce, create, 5 made, construct, assemble, market, advertise, distribute and sell Essure® without providing adequate 6 warnings and instructions concerning the use of Essure® so as to maximize sales and profits at the 7 expense of the public health and safety, in knowing, conscious, and deliberate disregard of the 8 foreseeable harm caused by Essure®. 9

As a direct and proximate result of one or more of these wrongful acts or omissions of 140. 10 Defendants, Plaintiff suffered profound injuries as alleged herein, required medical treatment, and 11 incurred and continues to incur medical and hospital expenses.

12 WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory 13 and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as 14 the Court deems appropriate pursuant to the common law and statutory law.

#### **FIFTH CAUSE OF ACTION**

#### STRICT LIABILITY

17 141. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set forth herein and further alleges as follows: 18

Defendants are manufacturers and/or suppliers of Essure® and are strictly liable to 19 142. Plaintiff for manufacturing, designing, formulating, testing, packaging, labeling, producing, creating, 20 making, constructing, assembling, marketing, advertising, distributing, selling and placing Essure® 21 into the stream of commerce. 22

23

15

16

Essure®, manufactured and/or supplied by Defendants, was defective in design or 143. formulation in that when it left the hands of the manufacturer and/or suppliers, it was unreasonably 24 dangerous. It was more dangerous than an ordinary consumer would expect and more dangerous 25 than other contraceptives.

- 26
- 27 28

#### 1 144. Essure® was defective in design or formulation in that, when it left the hands of the manufacturer and/or suppliers, the foreseeable risks exceeded the benefits associated with the design 2 or formulation. 3 145. Essure<sup>®</sup> was also defective due to inadequate warnings or instructions because the 4 manufacturer knew or should have known that Essure® created, among other things, a risk of 5 perforation and migration and associated infections or conditions and the Defendants failed to 6 adequately warn of these risks. 7 Essure® was defective due to inadequate pre-marketing testing. 146. 8 147. Defendants failed to provide adequate initial warnings and post-marketing warnings or 9 instructions after the manufacturer and/or supplier knew or should have known of the extreme risks 10 associated with Essure® and continues to promote Essure® in the absence of those adequate warnings. 148. As a direct and proximate result of one or more of these wrongful acts or omissions of 13 Defendants, Plaintiff suffered profound injuries, required medical treatment, and incurred and 14 continues to incur medical and hospital expenses. 15 WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory 16 and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as 17 the Court deems appropriate pursuant to the common law and statutory law. 18 SIXTH CAUSE OF ACTION **BREACH OF IMPLIED WARRANTY** 19 149. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set 20 forth herein and further alleges as follows: 21 150. Defendants manufactured, designed, formulated, tested, packaged, labeled, produced, 22 created, made, constructed, assembled, marketed, advertised, distributed and sold Essure® as safe for 23 use by the public at large, including Plaintiff, who purchased Essure<sup>®</sup>. Defendants knew the use for 24 which their product was intended and impliedly warranted the product to be of merchantable quality, 25 safe and fit for use. 26 151. Plaintiff reasonably relied on the skill and judgment of Defendants, and as such their 27 implied warranty, in using Essure®.

# Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 26 of 32

26

- 11
- 12

152. Contrary to same, Essure® was not of merchantable quality or safe or fit for its 1 intended use, because it is unreasonably dangerous and unfit for the ordinary purpose for which it 2 was used. 3 As a direct and proximate result of one or more of these wrongful acts or omissions of 153. 4 Defendants, Plaintiff suffered profound injuries, required medical treatment, and incurred and 5 continues to incur medical and hospital expenses. 6 WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory 7 and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as 8 the Court deems appropriate pursuant to the common law and statutory law. 9 **SEVENTH CAUSE OF ACTION** 10 **BREACH OF EXPRESS WARRANTY** 11 154. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set 12 forth herein and further alleges as follows: 13 155. The aforementioned designing, manufacturing, marketing, formulating, testing, 14 packaging, labeling, producing, creating, making, constructing, assembling, advertising, and 15 distributing of Essure® were expressly warranted to be safe by Defendants for Plaintiff and members 16 of the public generally. At the time of the making of these express warranties, Defendants warranted 17 Essure® to be in all respects safe, effective and proper for such purposes. 18 Essure® does not conform to these express warranties and representations because 156. Essure® is not safe or effective and may produce serious side effects. 19 As a direct and proximate result of one or more of these wrongful acts or omissions of 157. 20 Defendants, Plaintiff suffered profound injuries, required medical treatment and incurred and 21 continues to incur medical and hospital expenses. 22 WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory 23 and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as 24 the Court deems appropriate pursuant to the common law and statutory law. 25 **EIGHT CAUSE OF ACTION** 26 **NEGLIGENT MISREPRESENTATION** 27 28 27 COMPLAINT FOR DAMAGES AND DEMAND FOR JURY TRIAL

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 27 of 32

158. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set
 forth herein and further alleges as follows:
 159. Defendants, having undertaken the designing, manufacturing, marketing, formulating,
 testing, packaging, labeling, producing, creating, making, constructing, assembling, advertising, and

Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 28 of 32

distributing of Essure®, owed a duty to provide accurate and complete information regarding
Essure®.

7 8

9

160. Defendants falsely represented to Plaintiff that Essure® was an effective contraceptive option. The representations by Defendants were in fact false, as Essure® is not safe and is dangerous to the health of its users.

161. At the time the aforesaid representations were made, Defendants concealed
 information about the propensity of Essure® to cause great harm from Plaintiff and her health care
 providers.

12 162. Defendants negligently misrepresented claims regarding the safety and efficacy of
 13 Essure® despite the lack of information regarding same.

14 163. These misrepresentations were made by Defendants with the intent to induce Plaintiff
15 to use Essure<sup>®</sup>, which caused her injury.

16 164. At the time of Defendants' misrepresentations and omissions, Plaintiff was ignorant of
17 the falsity of these statements and reasonably believed them to be true.

18 165. Defendants breached their duties to Plaintiff by providing false, incomplete and/or
19 misleading information regarding their product.

20 166. Plaintiff reasonably believed Defendants' representations and reasonably relied on the
 accuracy of those representations when agreeing to treatment with Essure®.

167. As a direct and proximate result of one or more of these wrongful acts or omissions of
 Defendants, Plaintiff suffered profound injuries, required medical treatment, and incurred and
 continues to incur medical and hospital expenses.

WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as the Court deems appropriate pursuant to the common law and statutory law.

28

#### NINTH CAUSE OF ACTION

1	FRAUDULENT MISREPRESENTATION					
2	168. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set					
3	forth herein and further alleges as follows:					
4	169. Defendants, having undertaken the designing, manufacturing, marketing, formulating,					
5	testing, packaging, labeling, producing, creating, making, constructing, assembling, advertising, and					
6	distributing of Essure® described herein, owed a duty to provide accurate and complete information					
7	regarding Essure <sup>®</sup> .					
8	170. Defendants fraudulently misrepresented material facts and information regarding					
9	Essure® including, but not limited to, its propensity to cause serious physical harm.					
10	171. At the time of Defendants' fraudulent misrepresentations and omissions, Plaintiff was					
10	unaware and ignorant of the falsity of the statements and reasonably believed them to be true.					
	172. Defendants knew this information to be false, incomplete and misleading.					
12	173. Defendants intended to deceive and mislead Plaintiff so that she might rely on these					
13	fraudulent misrepresentations.					
14	174. Plaintiff had a right to rely on and did reasonably rely upon Defendants' deceptive,					
15	inaccurate and fraudulent misrepresentations.					
16	175. As a direct and proximate result of one or more of these wrongful acts or omissions of					
17	Defendants, Plaintiff suffered profound injuries, required medical treatment, and incurred and					
18	continues to incur medical and hospital expenses.					
19	WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory					
20	and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as					
21	the Court deems appropriate pursuant to the common law and statutory law.					
22	TENTH CAUSE OF ACTION					
23	FRAUD BY CONCEALMENT					
24	176. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set					
25	forth herein and further alleges as follows:					
26	177. Defendants had a duty and obligation to disclose to Plaintiff that Essure® was					
27	dangerous and likely to cause serious health consequences to users when used as prescribed.					
28						
	29 COMPLAINT FOR DAMAGES AND DEMAND FOR JURY TRIAL					

# Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 30 of 32

1	178. Defendants intentionally, willfully, and maliciously concealed and/or suppressed the					
2	facts set forth above from Plaintiff with the intent to defraud her as herein alleged.					
3	179. Neither Plaintiff nor her physicians were aware of the facts set forth above, and had					
4	they been aware of said facts would not have prescribed this product.					
5	180. As a proximate result of the concealment and/or suppression of the facts set forth					
6	above, Plaintiff has proximately sustained damage, as set forth herein.					
7	181. As a direct and proximate result of one or more of these wrongful acts or omissions of					
, 8	Defendants, Plaintiff suffered profound injuries, required medical treatment, and incurred and					
0 9	continues to incur medical and hospital expenses.					
	WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory					
10	and punitive damages, together with interest, costs of suit, attorneys' fees and all such other relief as					
11	the Court deems appropriate pursuant to the common law and statutory law.					
12	REQUEST FOR PUNITIVE DAMAGES					
13	182. Plaintiff incorporates by reference all other paragraphs of this complaint as if fully set					
14	forth herein and further alleges as follows:					
15	183. At all times relevant herein, Defendants:					
16	a. knew that Essure® was dangerous and ineffective;					
17	b. concealed the dangers and health risks from Plaintiff, physicians, pharmacists,					
18	other medical providers, the FDA, and the public at large;					
19	c. made misrepresentations to Plaintiff, her physicians, hospitals and medical					
20	providers and the public in general as previously stated herein as to the safety and efficacy of					
21	Essure®; and,					
22	d. with full knowledge of the health risks associated with Essure® and without					
23	adequate warnings of the same, manufactured, designed, formulated, tested, packaged, labeled,					
24	produced, created, made, constructed, assembled, marketed, advertised, distributed and sold Essure®					
25	for routine use.					
26	184. Defendants, by and through officers, directors, managing agents, authorized sales					
27	representatives, employees and/or other agents who engaged in malicious, fraudulent and oppressive					
27						
1	30					
	COMPLAINT FOR DAMAGES AND DEMAND FOR JURY TRIAL					

#### Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 31 of 32

conduct towards Plaintiff and the public, acted with willful and wanton and/or conscious and reckless 1 disregard for the safety of Plaintiff and the general public. 2

3

4

185. As a direct and proximate result of one or more of these wrongful acts or omissions of Defendants, Plaintiff suffered profound injuries that required medical treatment and incurred medical and hospital expenses, for which Plaintiff has become liable.

5 6

Defendants are liable jointly and/or severally for all general, special and compensatory 186. damages and equitable relief to which Plaintiff is entitled by law. Plaintiff seeks actual and punitive 7 damages from Defendants and alleges that the conduct of Defendants was committed with knowing, 8 conscious, reckless, deliberate and grossly negligent disregard for the rights and safety of consumers, 9 including Plaintiff herein, thereby entitling Plaintiff to punitive damages in an amount appropriate to 10 punish Defendants and deter them from similar conduct in the future.

11 WHEREFORE, Plaintiff demands judgment against Defendants for compensatory, statutory 12 and punitive damages, together with interest, costs of suit, attorney's fees and all such other relief as 13 the Court deems appropriate pursuant to the common law and statutory law.

14

#### **RELIEF REQUESTED**

15 WHEREFORE Plaintiff prays for judgment against Defendants and, as appropriate to each 16 cause of action alleged and as appropriate to the standing of Plaintiff, as follows:

17 1. Past and future general damages, the exact amount of which has yet to be ascertained, in an amount according to proof at the time of trial; 18

2. Past and future economic and special damages according to proof at trial;

3. Loss of earnings and impaired earning capacity according to proof at trial; 20

21

19

4. Medical expenses, past and future, according to proof at the time of trial;

5. Past and future pain and suffering damages, including mental and, emotional stress 22 arising from Plaintiff's physical injuries, according to proof at the time of trial; 23

6. Equitable relief as requested and/or as the Court deems just and proper;

7. Declaratory judgment that Defendants are liable to Plaintiff for all future evaluative, 25 monitoring, diagnostic, preventative, and corrective medical, surgical, and incidental expenses, costs 26 and losses caused by Defendants' wrongdoing;

27 28

# Case 5:15-cv-05598 Document 1 Filed 12/08/15 Page 32 of 32

1	8. Medical monitoring, whether denominated as damages or in the form of equitable							
2	relief according to proof at the time of trial;							
3	9. Punitive or exemplary damages according to proof at the time of trial;							
4	10. Costs of suit incurred herein;							
5		11.	Pre-judgment interest as provided by law; and					
6	12. Such other and further relief as the Court may deem just and proper.							
7	///							
8	///							
9			DEMAND FOR JURY TRIAL					
10		Plaint	iff hereby demands a trial by Jury.					
11								
12	Dated: December 8, 2015							
13								
14			s/Martin Schmidt					
15			By: Martin Schmidt MARTIN SCHMIDT, ESQ. (SBN 171673)					
16	mschmidt@nationalinjuryhelp.com SCHMIDT NATIONAL LAW GROUP							
17			4241 Jutland Dr. Suite 200 San Diego, CA 92117 Talaphana: 800 214 1010					
18			Telephone: 800.214.1010 Facsimile: 619.393.1777					
19								
20								
21								
22								
23								
24								
25								
26								
27								
28			32					
			COMPLAINT FOR DAMAGES AND DEMAND FOR JURY TRIAL					

# JS 44 (Rev. 12/12) cand rev (1/15/13) Case 5:15-cv-05598 Document 1-1 Filed 12/08/15 Page 1 of 2

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. *(SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)* 

I. (a) PLAINTIFFS			DEFENDANT	ſS		
	 XCEPT IN U.S. PLAINTIFF CA	, ,	County of Residence of First Listed Defendant (IN U.S. PLAINTIFF CASES ONLY) NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.			
(c) Attorneys (Firm Name, 1	Address, and Telephone Numbe	r)	Attorneys (If Know	n)		
II. BASIS OF JURISDI	CTION (Place an "X" in O	ne Box Only)			(Place an "X" in One Box for Plaintif	
□ 1 U.S. Government Plaintiff	□ 3 Federal Question (U.S. Government)	Not a Party)	(For Diversity Cases Only Citizen of This State	PTF DEF D 1 D 1 Incorporated or Pr of Business In 7		
□ 2 U.S. Government Defendant	☐ 4 Diversity (Indicate Citizenshi	ip of Parties in Item III)	Citizen of Another State	□ 2 □ 2 Incorporated and of Business In	Another State	
			Citizen or Subject of a Foreign Country	□ 3 □ 3 Foreign Nation		
IV. NATURE OF SUIT			FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES	
<ul> <li>110 Insurance</li> <li>120 Marine</li> <li>130 Miller Act</li> <li>140 Negotiable Instrument</li> <li>150 Recovery of Overpayment &amp; Enforcement of Judgment</li> <li>151 Medicare Act</li> </ul>	□ 330 Federal Employers' Product Liability		<ul> <li>☐ 625 Drug Related Seizure of Property 21 USC 88</li> <li>☐ 690 Other</li> </ul>		<ul> <li>375 False Claims Act</li> <li>400 State Reapportionment</li> <li>410 Antitrust</li> <li>430 Banks and Banking</li> <li>450 Commerce</li> <li>460 Deportation</li> <li>470 Racketeer Influenced and</li> </ul>	
<ul> <li>152 Recovery of Defaulted Student Loans (Excludes Veterans)</li> <li>153 Recovery of Overpayment of Veteran's Benefits</li> <li>160 Stockholders' Suits</li> <li>190 Other Contract</li> <li>195 Contract Product Liability</li> <li>196 Franchise</li> </ul>	Liability a 340 Marine 345 Marine Product Liability 350 Motor Vehicle 9355 Motor Vehicle Product Liability 360 Other Personal Injury 362 Personal Injury - Medical Malpractice	<ul> <li>368 Asbestos Personal Injury Product Liability</li> <li>PERSONAL PROPERT</li> <li>370 Other Fraud</li> <li>371 Truth in Lending</li> <li>380 Other Personal Property Damage</li> <li>385 Property Damage Product Liability</li> </ul>	Y ☐ 710 Fair Labor Standards Act 720 Labor/Management Relations 740 Railway Labor Act 751 Family and Medical Leave Act 790 Other Labor Litigation	<ul> <li>840 Trademark</li> <li>SOCIAL SECURITY</li> <li>861 HIA (1395ff)</li> <li>862 Black Lung (923)</li> <li>863 DIWC/DIWW (405(g))</li> <li>864 SSID Title XVI</li> <li>865 RSI (405(g))</li> </ul>	Corrupt Organizations 480 Consumer Credit 490 Cable/Sat TV 850 Securities/Commodities/ Exchange 890 Other Statutory Actions 891 Agricultural Acts 893 Environmental Matters 895 Freedom of Information Act 896 Arbitration	
REAL PROPERTY         210 Land Condemnation         220 Foreclosure         230 Rent Lease & Ejectment         240 Torts to Land         245 Tort Product Liability         290 All Other Real Property	CIVIL RIGHTS 440 Other Civil Rights 441 Voting 442 Employment 443 Housing/ Accommodations 445 Amer. w/Disabilities - Employment 446 Amer. w/Disabilities - Other 448 Education	PRISONER PETITIONS         Habeas Corpus:         ↓ 463 Alien Detainee         □ 510 Motions to Vacate Sentence         □ 530 General         □ 535 Death Penalty         Other:         □ 540 Mandamus & Other         □ 555 Prison Condition         □ 555 Prison Condition         □ 560 Civil Detainee - Conditions of Confinement	<ul> <li>791 Employee Retirement Income Security Act</li> <li>IMMIGRATION         <ul> <li>462 Naturalization Applicat</li> <li>465 Other Immigration Actions</li> </ul> </li> </ul>	FEDERAL TAX SUITS          870 Taxes (U.S. Plaintiff or Defendant)         871 IRS—Third Party         26 USC 7609	<ul> <li>899 Administrative Procedure Act/Review or Appeal of Agency Decision</li> <li>950 Constitutionality of State Statutes</li> </ul>	
V. ORIGIN (Place an "X" in	n One Box Only)	commentent			<u> </u>	
□ 1 Original □ 2 Re	moved from $\Box$ 3 te Court	Appellate Court	Reopened Ano (spec			
VI. CAUSE OF ACTION		•	filing (Do not cite jurisdictional s	statutes unless diversity):		
VII. REQUESTED IN COMPLAINT:	CHECK IF THIS UNDER RULE 2	IS A CLASS ACTION 3, F.R.Cv.P.	DEMAND \$	CHECK YES only JURY DEMAND	if demanded in complaint:	
VIII. RELATED CASI IF ANY	E(S) (See instructions):	JUDGE		DOCKET NUMBER		
DATE		SIGNATURE OF ATTO	ORNEY OF RECORD			
K20'F KXHKQP CN'CUUN PO GP (Place an "X" in One Box Only)		) SAN FRANCISCO/OAKI	LAND () SAN JOSE ()	EUREKA		

#### **INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44**

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- **I.(a) Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
- (b) County of Residence. For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)
- (c) Attorneys. Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".

II. Jurisdiction. The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below. United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here. United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box. Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes

precedence, and box 1 or 2 should be marked.

Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)

- **III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- **IV.** Nature of Suit. Place an "X" in the appropriate box. If the nature of suit cannot be determined, be sure the cause of action, in Section VI below, is sufficient to enable the deputy clerk or the statistical clerk(s) in the Administrative Office to determine the nature of suit. If the cause fits more than one nature of suit, select the most definitive.
- V. Origin. Place an "X" in one of the six boxes.

Original Proceedings. (1) Cases which originate in the United States district courts.

Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. When the petition for removal is granted, check this box.

Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.


Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date. Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.

Multidistrict Litigation. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407. When this box is checked, do not check (5) above.

- VI. Cause of Action. Report the civil statute directly related to the cause of action and give a brief description of the cause. Do not cite jurisdictional statutes unless diversity. Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service
- VII. Requested in Complaint. Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P. Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction. Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- VIII. Related Cases. This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

Date and Attorney Signature. Date and sign the civil cover sheet.

AO 440 (Rev. 06/12) Summons in a Civil Action



#### SUMMONS IN A CIVIL ACTION

To: (Defendant's name and address)

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date:

Signature of Clerk or Deputy Clerk

AO 440 (Rev. 06/12) Summons in a Civil Action (Page 2)

Civil Action No.

### **PROOF OF SERVICE**

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

	This summons for (nan	ne of individual and title, if any)				
was re	ceived by me on (date)					
	□ I personally served	the summons on the individu	al at (place)			
This summons for (name of individual and title, if any) was received by me on (date)  I personally served the summons on the individual at (place)  I personally served the summons on the individual at (place)  I left the summons at the individual's residence or usual place of abode with (name)  , a person of suitable age and discretion who resides the on (date), and mailed a copy to the individual's last known address; or I served the summons on (name of individual) designated by law to accept service of process on behalf of (name of organization)  On (date) on (date); or I returned the summons unexecuted because Other (specify):  My fees are \$ for travel and \$ for services, for a total of \$ I declare under penalty of perjury that this information is true.  Date:						
	□ I left the summons	at the individual's residence of	or usual place of abode with (name)			
	sides ther	e,				
			to the individual's last known address; or			
□ I served the sur		ons on (name of individual)			, who is	
	designated by law to a	accept service of process on b				
			on (date)	n (date); or ce of abode with (name)		
	$\Box$ I returned the summ	nons unexecuted because			; or	
	<b>Other</b> ( <i>specify</i> ):					
	My fees are \$	for travel and \$	for services, for a total of \$			
	I declare under penalty of perjury that this information is true.					
Date:						
			Server's signature			
			Printed name and title			

Server's address

Additional information regarding attempted service, etc: